Exact Mass: 410.2892908
Exact Mass Matches: 410.2892908
Found 460 metabolites which its exact mass value is equals to given mass value 410.2892908,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
gamma-Tocotrienol
gamma-Tocotrienol, also known as 7,8-dimethyltocotrienol, belongs to the class of organic compounds known as tocotrienols. These are vitamin E derivatives containing an unsaturated trimethyltrideca-3,7,11-trien-1-yl chain attached to the C6 atom of a benzopyran ring system. They differ from tocopherols that contain a saturated trimethyltridecyl chain. Thus, gamma-tocotrienol is considered to be a quinone lipid molecule. gamma-Tocotrienol is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. gamma-Tocotrienol targets cancer cells by inhibiting Id1, a key cancer-promoting protein. gamma-Tocotrienol was shown to trigger cell apoptosis and well as anti-proliferation of cancer cells. This mechanism was also observed in separate prostate cancer and melanoma cell line studies. Constituent of palm oil. Nutriceutical with anticancer props. and a positive influence on the blood lipid profile. gamma-Tocotrienol is found in many foods, some of which are rye, corn, rosemary, and common grape. Acquisition and generation of the data is financially supported in part by CREST/JST. γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment[1][2][3]. γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment[1][2][3].
beta-tocotrienol
LysoPA(16:0/0:0)
LysoPA(16:0/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293). Lysopa(16:0/0:0), also known as 1-palmitoyl lysophosphatidic acid or 1-hexadecanoyl-sn-glycero-3-phosphate, is a member of the class of compounds known as 1-acylglycerol-3-phosphates. 1-acylglycerol-3-phosphates are lysophosphatidic acids where the glycerol is esterified with a fatty acid at O-1 position. Thus, lysopa(16:0/0:0) is considered to be a glycerophosphate lipid molecule. Lysopa(16:0/0:0) is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Lysopa(16:0/0:0) can be found in a number of food items such as alfalfa, soy bean, banana, and barley, which makes lysopa(16:0/0:0) a potential biomarker for the consumption of these food products. Lysopa(16:0/0:0) can be found primarily throughout all human tissues. Lysopa(16:0/0:0) exists in all living species, ranging from bacteria to humans. In humans, lysopa(16:0/0:0) is involved in several metabolic pathways, some of which include cardiolipin biosynthesis CL(16:0/18:1(11Z)/18:0/18:1(9Z)), cardiolipin biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/16:0), cardiolipin biosynthesis CL(16:0/20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)), and cardiolipin biosynthesis CL(16:0/18:1(11Z)/18:0/18:1(11Z)). Lysopa(16:0/0:0) is also involved in several metabolic disorders, some of which include de novo triacylglycerol biosynthesis TG(16:0/24:0/20:4(8Z,11Z,14Z,17Z)), de novo triacylglycerol biosynthesis TG(16:0/22:2(13Z,16Z)/22:0), de novo triacylglycerol biosynthesis TG(16:0/15:0/18:3(9Z,12Z,15Z)), and de novo triacylglycerol biosynthesis TG(16:0/15:0/24:0).
Norethindrone enanthate
D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents Same as: D08285
epsilon-Tocopherol
Isolated from wheat bran oil. epsilon-Tocopherol is found in many foods, some of which are rye, coconut, rosemary, and fennel. epsilon-Tocopherol is found in american cranberry. epsilon-Tocopherol is isolated from wheat bran oi
(3beta,22E,24R)-3-Hydroxyergosta-5,8,22-trien-7-one
(3beta,22E,24R)-3-Hydroxyergosta-5,8,22-trien-7-one is found in mushrooms. (3beta,22E,24R)-3-Hydroxyergosta-5,8,22-trien-7-one is a constituent of Grifola frondosa (maitake) Constituent of Grifola frondosa (maitake). (3beta,22E,24R)-3-Hydroxyergosta-5,8,22-trien-7-one is found in mushrooms.
5,8-Epoxy-5,8-dihydro-10'-apo-b,y-carotene-3,10'-diol
5,8-Epoxy-5,8-dihydro-10-apo-b,y-carotene-3,10-diol is found in citrus. 5,8-Epoxy-5,8-dihydro-10-apo-b,y-carotene-3,10-diol is isolated from Persea americana (avocado) and from Valencia orange juice. Isolated from Persea americana (avocado) and from Valencia orange juice. 5,8-Epoxy-5,8-dihydro-10-apo-b,y-carotene-3,10-diol is found in citrus and fruits.
5,6-Epoxy-5,6-dihydro-10'-apo-b,y-carotene-3,10'-diol
5,6-Epoxy-5,6-dihydro-10-apo-b,y-carotene-3,10-diol is found in pomes. 5,6-Epoxy-5,6-dihydro-10-apo-b,y-carotene-3,10-diol is isolated from the peel of the ripe Golden Delicious apple. 5,6-Epoxy-5,6-dihydro-10-apo-b,y-carotene-3,10-diol isa metabolite of
LysoPA(0:0/16:0)
LysoPA(0:0/16:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).
(6alpha,22E)-6-Hydroxy-4,7,22-ergostatrien-3-one
(6beta,22E)-6-Hydroxy-4,7,22-ergostatrien-3-one is found in mushrooms. (6beta,22E)-6-Hydroxy-4,7,22-ergostatrien-3-one is a metabolite of Ganoderma lucidum (reishi).
N-Oleoyl Glutamine
C23H42N2O4 (410.31444120000003)
N-oleoyl glutamine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Oleic acid amide of Glutamine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Oleoyl Glutamine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Oleoyl Glutamine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
(2R)-2,5,8-Trimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol
(2R)-2,7,8-Trimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol
2-Pyridinemethanamine, N-((4-(1,4,8,11-tetraazacyclotetradec-1-ylmethyl)phenyl)methyl)-
Vesatolimod
C22H30N6O2 (410.24301199999996)
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C308 - Immunotherapeutic Agent > C2139 - Immunostimulant C254 - Anti-Infective Agent > C281 - Antiviral Agent
Norethisterone enanthate
1,25-Dihydroxy-16-ene-23-yne-vitamin D3
MG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/0:0)
MG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/0:0)
MG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/0:0)
MG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0)
MG(0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0)
MG(0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0)
MG(0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
DG(2:0/18:2(10E,12Z)+=O(9)/0:0)
DG(2:0/18:2(10E,12Z)+=O(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/18:2(10E,12Z)+=O(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/2:0/0:0)
DG(18:2(10E,12Z)+=O(9)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(10E,12Z)+=O(9)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/18:2(10E,12Z)+=O(9))
DG(2:0/0:0/18:2(10E,12Z)+=O(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/0:0/2:0)
DG(18:2(10E,12Z)+=O(9)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/18:2(9Z,11E)+=O(13)/0:0)
DG(2:0/18:2(9Z,11E)+=O(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/18:2(9Z,11E)+=O(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/2:0/0:0)
DG(18:2(9Z,11E)+=O(13)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(9Z,11E)+=O(13)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/18:2(9Z,11E)+=O(13))
DG(2:0/0:0/18:2(9Z,11E)+=O(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/0:0/2:0)
DG(18:2(9Z,11E)+=O(13)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/18:3(10,12,15)-OH(9)/0:0)
DG(2:0/18:3(10,12,15)-OH(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/18:3(10,12,15)-OH(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/2:0/0:0)
DG(18:3(10,12,15)-OH(9)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(10,12,15)-OH(9)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/18:3(10,12,15)-OH(9))
DG(2:0/0:0/18:3(10,12,15)-OH(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/0:0/2:0)
DG(18:3(10,12,15)-OH(9)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/18:3(9,11,15)-OH(13)/0:0)
DG(2:0/18:3(9,11,15)-OH(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/18:3(9,11,15)-OH(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/2:0/0:0)
DG(18:3(9,11,15)-OH(13)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(9,11,15)-OH(13)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/18:3(9,11,15)-OH(13))
DG(2:0/0:0/18:3(9,11,15)-OH(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/0:0/2:0)
DG(18:3(9,11,15)-OH(13)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
Sinensiaxanthin
Sinensiaxanthin is a member of the class of compounds known as sesterterpenoids. Sesterterpenoids are terpenes composed of five consecutive isoprene units. Sinensiaxanthin is practically insoluble (in water) and an extremely weak acidic compound (based on its pKa). Sinensiaxanthin can be found in apple and sweet orange, which makes sinensiaxanthin a potential biomarker for the consumption of these food products.
(+)-Makassaric acid
A meroterpenoid isolated from the marine sponge Acanthodendrilla sp. It exhibits inhibitory activity against the enzyme mitogen-activated protein kinase-activated protein kinase 2 (EC 2.7.11.1).
(+)-Subersic acid
A meroterpenoid that is 4,4,7,8a-tetramethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalene substituted by a (3E)-5-(5-carboxy-2-hydroxyphenyl)-3-methylpent-3-en-1-yl moiety at position 8. It is isolated from the marine sponge Acanthodendrilla and exhibits inhibitory activity against the enzyme mitogen-activated protein kinase-activated protein kinase 2 (EC 2.7.11.1).
methyl-13S,15-dihydroxy-14R-acetoxy-1(10)-ent-halimen-18-oate
(2E,6E,10E)-2-(9-hydroxygeranylgeranyl)-6-methyl-1,4-benzoquinone|9-hydroxysargaquinone|Hydroxysargaquinone
3-[5-(2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl)-3-methylpent-2-enyl]-4-hydroxybenzoic acid
1beta,1beta:21,23-diepoxy-7alpha-hydroxy-24,25,26,27-tetranor-apotirucalla-14,20,22-trien-3-one
methyl-2alpha-acetoxy-3alpha,9beta-dihydroxy-9-epi-labd-13(E)-en-15-oate
6alpha-({4-acetoxy}-7Z-coumaryloxy)eudesm-4(14)-ene
24-exomethylenecalicoferol E|24-exomethylenwcalicoferol E|24-methylenecalicoferol E
(rel-3S,5S,8R,9R,10S,13S,15S,16R)-3-acetoxy-9,13; 15,16-diepoxy-15,16-dimethoxylabdane|vitextrifolin A
(25R)-19-norspirosta-1,3,5(10)-triene-4-methyl-2-ol
(2E,2E)-4-hydroxy-3-(3,7-dimethylocta-2,6-dienyl)-5-(3,7-dimethylocta-2,6-dienyl)benzoic acid|3,5-digeranyl-4-hydroxybenzoic acid|myrsinoic acid E
1-(2,4,6-trihydroxyphenyl)-5,8,11,14,17-eicosapentaen-1-one
methyl (22E)-3-oxo-24-norcholesta-1,4,22-trien-26-one
(20S)-20-hydroxyergosta-1,4,24(28)-trien-3-one|methyl (20S)-20-hydroxyergosta-1,4,24(28)-trien-3-one
(22E,24R)-ergosta-7,22-dien-3,6-dione|(22E,24R)-ergosta-7,22-diene-3,6-dione|cyathisterone
(2E,6E,10E)-4-hydroxy-3-(3,7,11,15-tetramethyl-hexadeca-2,6,10,14-tetraenyl)-benzoic acid|(2E,6E,10E)-4-hydroxy-3-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)benzoic acid|3-geranylgeranyl-4-hydroxybenzoic acid|4-Hydroxy-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)benzoic acid|4-hydroxy-3-(E,E,E-3,7,11,15-tetramethyl-hexadeca-2,6,10,14-tetraenyl)benzoic acid|4-Hydroxy-3-tetraprenylbenzoesaeure|4-hydroxy-3-tetraprenylbenzoicacid
1-(1-methylethyl)-4-methyl-3-cyclohexenyl 3,5-bis(3-methyl-2-butenyl)-4-hydroxybenzoate
tilorone
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals D007155 - Immunologic Factors > D007369 - Interferon Inducers D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent D000893 - Anti-Inflammatory Agents D000970 - Antineoplastic Agents Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels[1][2][3][4][5].
gamma-Tocotrienol
gamma-Tocotrienol, also known as 7,8-dimethyltocotrienol, belongs to the class of organic compounds known as tocotrienols. These are vitamin E derivatives containing an unsaturated trimethyltrideca-3,7,11-trien-1-yl chain attached to the C6 atom of a benzopyran ring system. They differ from tocopherols that contain a saturated trimethyltridecyl chain. Thus, gamma-tocotrienol is considered to be a quinone lipid molecule. gamma-Tocotrienol is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. gamma-Tocotrienol targets cancer cells by inhibiting Id1, a key cancer-promoting protein. gamma-Tocotrienol was shown to trigger cell apoptosis and well as anti-proliferation of cancer cells. This mechanism was also observed in separate prostate cancer and melanoma cell line studies. Gamma-tocotrienol is a tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2, 7 and 8 and a farnesyl chain at position 2. A vitamin E family member that has potent anti-cancer properties against a wide-range of cancers. It has a role as an antioxidant, an antineoplastic agent, a plant metabolite, a radiation protective agent, an apoptosis inducer and a hepatoprotective agent. It is a tocotrienol and a vitamin E. gamma-Tocotrienol is a natural product found in Amaranthus cruentus, Triadica sebifera, and other organisms with data available. A tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2, 7 and 8 and a farnesyl chain at position 2. A vitamin E family member that has potent anti-cancer properties against a wide-range of cancers. Constituent of palm oil. Nutriceutical with anticancer props. and a positive influence on the blood lipid profile. gamma-Tocotrienol is found in many foods, some of which are rye, corn, rosemary, and common grape. γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment[1][2][3]. γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment[1][2][3].
γ-Tocotrienol
γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment[1][2][3]. γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment[1][2][3].
Pro Pro Val Val
Pro Val Pro Val
Pro Val Val Pro
Val Pro Pro Val
Val Pro Val Pro
Val Val Pro Pro
(5Z,7E,22E)-(1S,3R)-1,3-dihydroxy-26,27-cyclo-9,10-seco-5,7,10(19),22-cholestatetraen-24-one
(5Z,7E)-(1S,3R)-24,25-epoxy-9,10-seco-5,7,10(19)-cholestatrien-22-yne-1,3-diol
(5Z,7E)-(1S,3R)-25,26-epoxy-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3-diol
(5Z,7E)-(1S,3R,20S)-25,26-epoxy-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3-diol
(5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-1,3,25-triol
3beta-Hydroxy-(22E,24R)-ergosta-5,8,22-trien-7-one
(6alpha,22E)-6-Hydroxy-4,7,22-ergostatrien-3-one
5,8-Epoxy-5,8-dihydro-10'-apo-b,y-carotene-3,10'-diol
5,6-Epoxy-5,6-dihydro-10'-apo-b,y-carotene-3,10'-diol
(22E)-1alpha-hydroxy-24-oxo-26,27-cyclo-22,23-didehydrovitamin D3
24,25-epoxy-1alpha-hydroxy-22,22,23,23-tetradehydrovitamin D3
25,26-epoxy-1alpha-hydroxy-23,23,24,24-tetradehydrovitamin D3
25,26-epoxy-1alpha-hydroxy-23,23,24,24-tetradehydro-20-epivitamin D3
2-eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoylphloroglucinol
trans,trans-3,4,5-trifluorophenyl 4-pentylbicyclohexyl-4-carboxylate
Pyridinium,1-[[(1-oxooctadecyl)amino]methyl]-, chloride (1:1)
methyl trimethyl-3-[(1-oxododecyl)amino]propylammonium sulphate
C19H42N2O5S (410.28142820000005)
1-(2-ethoxyethyl)-2-[[4-(4-pyrazol-1-ylbutyl)piperazin-1-yl]methyl]benzimidazole
1,1-Biphenyl, 4-[(trans,trans)-4-butyl[1,1-bicyclohexyl]-4-yl]-3,4-difluoro-
1-Ethoxy-2,3-difluoro-4-[[4-(trans-4-pentylcyclohexyl)phenyl]ethynyl]benzene
C27H32F2O (410.24210859999994)
trans-4-Pentylcyclohexanecarboxylic acid 2,3-dicyano-4-(pentyloxy)phenyl ester
(Z)-4-[3-(2-CHLORO-9H-THIOXANTHEN-9-YLIDENE)PROPYL]PIPERAZINE-1-ETHANOLDIHYDROCHLORIDE
(2R)-2-hydroxy-3-(phosphonooxy)propyl hexadecanoate
Norethisterone enanthate
D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents
GS-9620
C22H30N6O2 (410.24301199999996)
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C308 - Immunotherapeutic Agent > C2139 - Immunostimulant C254 - Anti-Infective Agent > C281 - Antiviral Agent
CHEBI:33277
γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment[1][2][3]. γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment[1][2][3].
(2R)-2,7,8-Trimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol
[(2R)-2-(hexadecanoyloxy)-3-hydroxypropoxy]phosphonic acid
Norethisterone enanthate
3,4-Dihydro-2,7,8-trimethyl-2-[(3E,7E)-4,8,12-trimethyl-3,7,11-tridecatrienyl]-2H-1-benzopyran-6-ol
5-amino-2-[[(E)-octadec-9-enoyl]amino]-5-oxopentanoic acid
C23H42N2O4 (410.31444120000003)
[(2S)-1-acetyloxy-3-hydroxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-2-acetyloxy-3-hydroxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2R)-3-acetyloxy-2-hydroxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-3-acetyloxy-2-hydroxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-1-acetyloxy-3-hydroxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2S)-2-acetyloxy-3-hydroxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2R)-3-acetyloxy-2-hydroxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2S)-3-acetyloxy-2-hydroxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[3-carboxy-2-[(3E,5E,11E)-14-carboxytetradeca-3,5,11-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(9E,11E,13E)-14-carboxytetradeca-9,11,13-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(3E,6E,9E)-14-carboxytetradeca-3,6,9-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(7E,10E,13E)-14-carboxytetradeca-7,10,13-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(4E,6E,8E)-14-carboxytetradeca-4,6,8-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(5E,8E,11E)-14-carboxytetradeca-5,8,11-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(2E,6E,10E)-14-carboxytetradeca-2,6,10-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(5E,7E,9E)-14-carboxytetradeca-5,7,9-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(3E,5E,7E)-14-carboxytetradeca-3,5,7-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-Carboxy-2-[5-(3,4-dimethyl-5-pentylfuran-2-yl)pentanoyloxy]propyl]-trimethylazanium
C23H40NO5+ (410.29063300000007)
[3-Carboxy-2-[6-(5-hexylfuran-2-yl)hexanoyloxy]propyl]-trimethylazanium
C23H40NO5+ (410.29063300000007)
[3-Carboxy-2-[7-(3,4-dimethyl-5-propylfuran-2-yl)heptanoyloxy]propyl]-trimethylazanium
C23H40NO5+ (410.29063300000007)
[3-Carboxy-2-[7-(5-pentylfuran-2-yl)heptanoyloxy]propyl]-trimethylazanium
C23H40NO5+ (410.29063300000007)
[2-[8-(5-Butylfuran-2-yl)octanoyloxy]-3-carboxypropyl]-trimethylazanium
C23H40NO5+ (410.29063300000007)
(5Z)-5-[(2E)-2-[1-(6-hydroxy-6-methylhept-4-yn-2-yl)-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
Minabeolide 4
A withanolide that is (22R,25S)-22,26-epoxycholesta-1,4-dien-26-one substituted by an oxo group at position 3. Isolated from Paraminabea acronocephala,it exhibits anti-inflammatory activity.
(22E,24R)-ergosta-7,22-diene-3,6-dione
A 3-oxo Delta(7)-steroid that is (22E)-ergosta-7,22-diene substituted by oxo groups at positions 3 and 6. It has been isolated from Penicillium commune.
7-Hexyl-3-methyl-8-(4-phenyl-1-piperazinyl)purine-2,6-dione
C22H30N6O2 (410.24301199999996)
N-[2-[4-(4-fluorophenyl)-1-piperazinyl]-2-(3-pyridinyl)ethyl]cyclohexanecarboxamide
C24H31FN4O (410.24817679999995)
5-tert-butyl-N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2,5-dimethylphenyl)-3-methyl-2-furancarboxamide
benzoic acid [3-hydroxy-10-(hydroxymethyl)-13-methyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] ester
N-Benzyl-3-[(2S,5aS,8aR)-6-(1H-imidazol-2-ylmethyl)-1-methyl-5-oxodecahydropyrrolo[3,2-E][1,4]diazepin-2-yl]propanamide
C22H30N6O2 (410.24301199999996)
1,3-dihydroxypropan-2-yl (5Z,8Z,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
[3-carboxy-2-[(11E,14E)-heptadeca-11,14-dienoyl]oxypropyl]-trimethylazanium
C24H44NO4+ (410.32701640000005)
(E)-3-(((quinolin-8-ylmethylene)amino)oxy)butyl undec-10-enoate
3-[[(3R,5R,7S,8E,10E,12E)-3-amino-5-hydroxy-7-methoxyoctadeca-8,10,12-trienoyl]amino]propanoic acid
3-(3,7,11,15-Tetramethyl-2,6,10,14-hexadecatetrenyl)-4-hydroxybenzoic acid
[2-(Butanoylamino)-3-hydroxynonyl] 2-(trimethylazaniumyl)ethyl phosphate
C18H39N2O6P (410.25456040000006)
(2-Acetamido-3-hydroxyundecyl) 2-(trimethylazaniumyl)ethyl phosphate
C18H39N2O6P (410.25456040000006)
[3-Hydroxy-2-(propanoylamino)decyl] 2-(trimethylazaniumyl)ethyl phosphate
C18H39N2O6P (410.25456040000006)
(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-7,10,13,16,19,22,25-heptaenoic acid
[3-Hydroxy-2-(pentanoylamino)octyl] 2-(trimethylazaniumyl)ethyl phosphate
C18H39N2O6P (410.25456040000006)
(1-hydroxy-3-propanoyloxypropan-2-yl) (9Z,12Z)-octadeca-9,12-dienoate
(1-butanoyloxy-3-hydroxypropan-2-yl) (9Z,12Z)-heptadeca-9,12-dienoate
(1-acetyloxy-3-hydroxypropan-2-yl) (9Z,12Z)-nonadeca-9,12-dienoate
(1-hydroxy-3-pentanoyloxypropan-2-yl) (9Z,12Z)-hexadeca-9,12-dienoate
1-Palmitoylglycerol 3-phosphate
A monoacylglycerol phosphate having palmitoyl as the acyl group on O-1 and with the phosphate group on O-3.
1-Palmitoyl-sn-glycerol 3-phosphate
A 1-acyl-sn-glycerol 3-phosphate having palmitoyl as the acyl group.
e-Tokoferol
A tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2, 5 and 8 and a farnesyl chain at position 2. It has been isolated from various cultivars of wheat.
(3beta,22E,24R)-3-Hydroxyergosta-5,8,22-trien-7-one
5,8-Epoxy-5,8-dihydro-10-apo-b,y-carotene-3,10-diol
5,6-Epoxy-5,6-dihydro-10-apo-b,y-carotene-3,10-diol
lysophosphatidic acid 16:0
A lysophosphatidic acid in which the acyl group (position not specified) contains 16 carbons and no double bonds.
TG(20:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
DG(21:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
3-[(2,4b,8,8,10a-pentamethyl-4,4a,5,6,7,8a,9,10-octahydro-1h-phenanthren-1-yl)methyl]-4-hydroxybenzoic acid
(13e)-2-oxatricyclo[20.2.2.1³,⁷]heptacosa-1(24),3,5,7(27),13,22,25-heptaene-5,24,25-triol
10-hydroxy-1,1,4a,6a,8,12b-hexamethyl-3h,4h,4bh,5h,6h,12h,12ah,13h,14h,14ah-naphtho[2,1-a]xanthen-2-one
(1s,2s,5s,14s,15r,18r,19s)-10-hydroxy-5,15,19-trimethyl-6,21-dioxahexacyclo[17.3.3.0¹,¹⁸.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]pentacosa-7,9,11-trien-20-one
(1s,3as,3bs,9ar,9bs,11as)-1-[(2s)-2-hydroxy-6-methyl-5-methylideneheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one
2-(6-hydroxy-4,8,12-trimethyltrideca-3,7,11-trien-1-yl)-2,8-dimethylchromen-6-ol
(2s)-6-methoxy-2,8-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4-dihydro-1-benzopyran
2-[(2e,6e,9r,10e)-9-hydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-6-methylcyclohexa-2,5-diene-1,4-dione
3-(3,7-dimethyloct-6-en-1-yl)-2-hydroxy-4-methoxy-6-(2-phenylethyl)benzoic acid
1-(2,5-dihydroxy-3-methylphenyl)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-5-one
(2s,4as,4bs,6as,11as,11bs,13ar)-2-hydroxy-1,1,4a,6a,9,11b-hexamethyl-2h,3h,4h,4bh,5h,6h,11h,11ah,12h,13h,13ah-indeno[2,1-a]phenanthrene-7,10-dione
(1r,7s,9as,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-4-one
(1r,3ar,3br,9ar,9br,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-3b-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one
3-[(3z,6z)-14-(2,3-dihydroxyphenyl)tetradeca-3,6-dien-1-yl]benzene-1,2-diol
methyl 4,6-dimethyl-7-[3,6,8-trimethyl-7-oxo-2-(2-oxopropyl)-5,6,8,8a-tetrahydro-1h-naphthalen-1-yl]hepta-2,4,6-trienoate
(2s,3r,4s,5r,6r)-2-{[(1ar,4r,4as,7r,7as,7bs)-1,1,4,7-tetramethyl-octahydro-1ah-cyclopropa[e]azulen-4-yl]oxy}-4,5-dihydroxy-6-methyloxan-3-yl acetate
3-[5-(2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl)-3-methylpent-2-en-1-yl]-4-hydroxybenzoic acid
(2s,3r,4s,5r,6r)-2-({2-[(2r,4as)-4a,8-dimethyl-2,3,4,5,6,7-hexahydro-1h-naphthalen-2-yl]propan-2-yl}oxy)-4,5-dihydroxy-6-methyloxan-3-yl acetate
methyl 5-[7-(acetyloxy)-1,6-dihydroxy-2,5,5,8a-tetramethyl-hexahydro-2h-naphthalen-1-yl]-3-methylpent-2-enoate
13-(6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl)-2,6,10-trimethyltrideca-2,6,10-trien-5-one
6β-hydroxyergosta-4,7,22-trien-3-one
{"Ingredient_id": "HBIN012274","Ingredient_name": "6\u03b2-hydroxyergosta-4,7,22-trien-3-one","Alias": "NA","Ingredient_formula": "C28H42O2","Ingredient_Smile": "NA","Ingredient_weight": "410.63","OB_score": "25.38516555","CAS_id": "68378-35-8","SymMap_id": "SMIT12077","TCMID_id": "NA","TCMSP_id": "MOL011142","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-[(2e,6e,10z)-12-hydroxy-3,7-dimethyl-11-(4-methylpent-3-en-1-yl)dodeca-2,6,10-trien-1-yl]-5-methylcyclohexa-2,5-diene-1,4-dione
(9ar,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,5ah,6h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,7-dione
(3r,6s,9r,12s)-3,6,9-triisopropyl-12-(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-1,4,7,10-tetraene-2,5,8,11-tetrol
(1r,3ar,7s,9as,11ar)-1-[(2r,3e,5s)-5,6-dimethylhept-3-en-2-yl]-7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-4-one
4-hydroxy-3-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)benzoic acid
tricyclo[20.2.2.0²,⁷]hexacosa-1(24),2,4,6,11,22,25-heptaene-3,5,24,25-tetrol
methyl (2e,4e,6e)-7-[(1r,6r,8s,8as)-3,6,8-trimethyl-7-oxo-2-(2-oxopropyl)-5,6,8,8a-tetrahydro-1h-naphthalen-1-yl]-4,6-dimethylhepta-2,4,6-trienoate
(1r,2r,4r,12r,13r,16z)-13-hydroxy-11,22-diazapentacyclo[11.11.2.1²,²².0²,¹².0⁴,¹¹]heptacosa-5,16,25-triene-25-carbaldehyde
C26H38N2O2 (410.29331279999997)
(1r,2r,3s,5s,8r,10r,11r,15r,16s)-15-(furan-3-yl)-10-hydroxy-2,7,7,11,16-pentamethyl-4-oxapentacyclo[9.7.0.0²,⁸.0³,⁵.0¹²,¹⁶]octadec-12-en-6-one
(2e,7e)-10-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-3,7-dimethyl-2-(2-methylprop-1-en-1-yl)deca-2,7-dienal
1-(2-hydroxy-6-methyl-5-methylideneheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one
2-[12-hydroxy-3,7-dimethyl-11-(4-methylpent-3-en-1-yl)dodeca-2,6,10-trien-1-yl]-5-methylcyclohexa-2,5-diene-1,4-dione
(4s,4ar,5s,7r,8r,8as)-2,5,8-trihydroxy-4-(3-hydroxypropanoyl)-4,7-dimethyl-3-[(2r)-octan-2-yl]-4a,5,6,7,8,8a-hexahydronaphthalen-1-one
2-(8-hydroxy-4,8,12-trimethyltrideca-3,6,11-trien-1-yl)-2,8-dimethylchromen-6-ol
methyl (2s,3e,5r)-5-[(1r,3as,3bs,9ar,9bs,11ar)-9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhex-3-enoate
3-{[(1r,4as,4bs,8as,10ar)-2,4b,8,8,10a-pentamethyl-4,4a,5,6,7,8a,9,10-octahydro-1h-phenanthren-1-yl]methyl}-4-hydroxybenzoic acid
(3r,3ar,5r,8s,11br)-3-[(2s,3e,5s)-5,6-dimethylhept-3-en-2-yl]-3a,6-dimethyl-1h,2h,3h,4h,5h,7h,8h,9h,10h,11bh-cyclopenta[a]anthracene-5,8-diol
15-(furan-3-yl)-10-hydroxy-2,7,7,11,16-pentamethyl-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadeca-3,12-dien-5-one
(1r,2r,4r,5z,12r,13s,16z)-13-hydroxy-11,22-diazapentacyclo[11.11.2.1²,²².0²,¹².0⁴,¹¹]heptacosa-5,16,25-triene-25-carbaldehyde
C26H38N2O2 (410.29331279999997)
methyl (2e)-5-[(1s,2r,4as,6s,7r,8as)-7-(acetyloxy)-1,6-dihydroxy-2,5,5,8a-tetramethyl-hexahydro-2h-naphthalen-1-yl]-3-methylpent-2-enoate
(4ar,4br,6as,12as,12br,14ar)-10-hydroxy-1,1,4a,6a,8,12b-hexamethyl-3h,4h,4bh,5h,6h,12h,12ah,13h,14h,14ah-naphtho[2,1-a]xanthen-2-one
10-hydroxy-5,15,19-trimethyl-6,21-dioxahexacyclo[17.3.3.0¹,¹⁸.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]pentacosa-7,9,11-trien-20-one
(1s,2s,3r,4r,5r,7s,8r,11s,14r,15r,17s)-15-hydroxy-14-methoxy-5,8,11,15-tetramethyl-10,18-dioxatetracyclo[9.7.0.0²,⁷.0³,¹⁷]octadecan-4-yl acetate
(2e,6z,10e)-1-(2,5-dihydroxy-3-methylphenyl)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-5-one
(1r,3ar,7s,9as,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-4-one
2-hydroxy-1,1,4a,6a,9,11b-hexamethyl-2h,3h,4h,4bh,5h,6h,11h,11ah,12h,13h,13ah-indeno[2,1-a]phenanthrene-7,10-dione
2-oxatricyclo[20.2.2.1³,⁷]heptacosa-1(24),3,5,7(27),13,22,25-heptaene-5,24,25-triol
(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-14',17'-dien-16'-one
3,5-bis[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-4-hydroxybenzoic acid
17,19-dihydroxy-4,8,12-trimethyl-14-(2-methylprop-1-en-1-yl)bicyclo[13.2.2]nonadeca-1(17),3,7,11,15(19)-pentaene-16,18-dione
tricyclo[20.2.2.0²,⁷]hexacosa-1(24),2,4,6,13,22,25-heptaene-3,5,24,25-tetrol
2,6,11,14-tetramethyl-5-propyl-4,13,19,20-tetraoxatricyclo[14.2.1.1⁷,¹⁰]icosane-3,12-dione
(1r,3ar,7s,9as,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthrene-7-peroxol
methyl 5-{9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methylhex-3-enoate
3,5-bis(3,7-dimethylocta-2,6-dien-1-yl)-4-hydroxybenzoic acid
(6e,10e)-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-2,6,10-trien-5-one
15-(furan-3-yl)-10-hydroxy-2,7,7,11,16-pentamethyl-4-oxapentacyclo[9.7.0.0²,⁸.0³,⁵.0¹²,¹⁶]octadec-12-en-6-one
1-{15-hydroxy-5-methyl-19-oxapentacyclo[12.3.2.0¹,¹³.0²,¹⁰.0⁵,⁹]nonadeca-6,10-dien-6-yl}-5-methyl-4-methylidenehexan-1-one
(2r,7r)-1-(acetyloxy)-7-methyl-3-methylidene-10-[(2s)-2,6,6-trimethyloxan-2-yl]decan-2-yl acetate
1-(5,6-dimethylhept-3-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,7-dione
(3e,7z,11e,14s)-17,19-dihydroxy-4,8,12-trimethyl-14-(2-methylprop-1-en-1-yl)bicyclo[13.2.2]nonadeca-1(17),3,7,11,15(19)-pentaene-16,18-dione
(1s,2s,5s,14s,15r,18r,19r)-10-hydroxy-5,15,19-trimethyl-6,21-dioxahexacyclo[17.3.3.0¹,¹⁸.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]pentacosa-7,9,11-trien-20-one
(2s)-6-methoxy-2,8-dimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trien-1-yl)-3,4-dihydro-1-benzopyran
2-[15-(acetyloxy)pentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid
3-[(3r)-3,7-dimethyloct-6-en-1-yl]-2-hydroxy-4-methoxy-6-(2-phenylethyl)benzoic acid
2-[(2e,6e)-12-hydroxy-3,7-dimethyl-11-(4-methylpent-3-en-1-yl)dodeca-2,6,10-trien-1-yl]-5-methylcyclohexa-2,5-diene-1,4-dione
(1s,2s,5s,6r,7s,10r,11s,14r,16r)-2,6,11,14-tetramethyl-5-propyl-4,13,19,20-tetraoxatricyclo[14.2.1.1⁷,¹⁰]icosane-3,12-dione
1-[(1s,4ar,4br,6as,12as,12br,14ar)-10-hydroxy-1,4a,6a,12b-tetramethyl-2h,3h,4h,4bh,5h,6h,12h,12ah,13h,14h,14ah-naphtho[2,1-a]xanthen-1-yl]ethanone
methyl (3e,5r)-5-[(1r,3as,3bs,9ar,9bs,11ar)-9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhex-3-enoate
9a,11a-dimethyl-1-[(2r)-6-methyl-5-oxohept-6-en-2-yl]-1h,2h,3h,3ah,3bh,4h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,7-dione
(2s)-2,6,7-trimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4-dihydro-1-benzopyran-8-ol
(1s,2s,4ar,8as)-2-isopropyl-4a-methyl-8-methylidene-octahydronaphthalen-1-yl 3-[4-(acetyloxy)phenyl]prop-2-enoate
(3e,7e,11e,14s)-17,19-dihydroxy-4,8,12-trimethyl-14-(2-methylprop-1-en-1-yl)bicyclo[13.2.2]nonadeca-1(17),3,7,11,15(19)-pentaene-16,18-dione
3-[(1r,2r,3s,4as,6r,8r,8as)-2-[(2r)-butan-2-yl]-3,6-dihydroxy-1,3,6,8-tetramethyl-4-oxo-hexahydronaphthalen-1-yl]-3-oxopropyl acetate
(1r,2s,3r,4r,5r,7s,8s,11r,14r,15r,17r)-15-hydroxy-14-methoxy-5,8,11,15-tetramethyl-10,18-dioxatetracyclo[9.7.0.0²,⁷.0³,¹⁷]octadecan-4-yl acetate
1-(acetyloxy)-7-methyl-3-methylidene-10-(2,6,6-trimethyloxan-2-yl)decan-2-yl acetate
(2r)-2-[(3e,6r,7e)-6-hydroxy-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-2,8-dimethylchromen-6-ol
(13e)-tricyclo[20.2.2.0²,⁷]hexacosa-1(24),2,4,6,13,22,25-heptaene-3,5,24,25-tetrol
(4ar,4br,8as,9r,10ar)-2-(3-hydroxy-4-methylphenyl)-4b,8,8,10a-tetramethyl-4,4a,5,6,7,8a,9,10-octahydro-1h-phenanthren-9-yl acetate
1-[(1s,2s,5s,9s,13r,14r,15s)-15-hydroxy-5-methyl-19-oxapentacyclo[12.3.2.0¹,¹³.0²,¹⁰.0⁵,⁹]nonadeca-6,10-dien-6-yl]-5-methyl-4-methylidenehexan-1-one
4-hydroxy-5-methyl-3-[(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]cyclohexa-3,5-diene-1,2-dione
(1r,5ar,7s,9as,11ar)-7-hydroxy-9a,11a-dimethyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-1h,2h,5h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-4-one
(1r)-1-isopropyl-4-methylcyclohex-3-en-1-yl 4-hydroxy-3,5-bis(3-methylbut-2-en-1-yl)benzoate
1-(5,6-dimethylhept-3-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthrene-7-peroxol
3-{5-[(4as,8as)-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpent-2-en-1-yl}-4-hydroxybenzoic acid
(1s,2s,5r,6r,9s,10s,15s,19s)-5-methyl-6-[(2r)-6-methyl-5-methylideneheptan-2-yl]-16-oxapentacyclo[13.2.2.0¹,¹³.0²,¹⁰.0⁵,⁹]nonadeca-11,13-dien-19-ol
(2e,10e)-1-(2,5-dihydroxy-3-methylphenyl)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-5-one
4-hydroxy-3-[(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]benzoic acid
(2e,6e,10e)-13-[(2s)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-2,6,10-trienal
(1r,2r,4r,5z,13s,16z)-13-hydroxy-11,22-diazapentacyclo[11.11.2.1²,²².0²,¹².0⁴,¹¹]heptacosa-5,16,25-triene-25-carbaldehyde
C26H38N2O2 (410.29331279999997)
(4as,11as,11bs,13ar)-2-hydroxy-1,1,4a,6a,9,11b-hexamethyl-2h,3h,4h,4bh,5h,6h,11h,11ah,12h,13h,13ah-indeno[2,1-a]phenanthrene-7,10-dione
1-(5,6-dimethylhept-3-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,5ah,6h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,7-dione
(1r,2r,8s,10r,11r,15r,16s)-15-(furan-3-yl)-10-hydroxy-2,7,7,11,16-pentamethyl-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadeca-3,12-dien-5-one
2-{[2-(4a,8-dimethyl-2,3,4,5,6,7-hexahydro-1h-naphthalen-2-yl)propan-2-yl]oxy}-4,5-dihydroxy-6-methyloxan-3-yl acetate
(4r,7z,11z,15z)-19-hydroxy-3,3,7,11,15-pentamethyl-2-oxatricyclo[16.3.1.0⁴,²¹]docosa-1(21),7,11,15,18-pentaene-20,22-dione
(2e,6e,10e)-1-(2,5-dihydroxy-3-methylphenyl)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-5-one
2-hydroxy-5-methyl-3-[(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]cyclohexa-2,5-diene-1,4-dione
(1r,3ar,7s,9as,11ar)-1-[(2s,3e,5s)-5,6-dimethylhept-3-en-2-yl]-7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-4-one
(3z,7z,11z,14s)-17,19-dihydroxy-4,8,12-trimethyl-14-(2-methylprop-1-en-1-yl)bicyclo[13.2.2]nonadeca-1(17),3,7,11,15(19)-pentaene-16,18-dione
(2e,6e,10e)-13-(6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienal
1-(2,4,6-trihydroxyphenyl)icosa-5,8,11,14,17-pentaen-1-one
15-hydroxy-14-methoxy-5,8,11,15-tetramethyl-10,18-dioxatetracyclo[9.7.0.0²,⁷.0³,¹⁷]octadecan-4-yl acetate
(13z)-tricyclo[20.2.2.0²,⁷]hexacosa-1(24),2,4,6,13,22,25-heptaene-3,5,24,25-tetrol
3-{[(1s,4as,5r,8as)-2,5,8a-trimethyl-5-(4-methylpent-3-en-1-yl)-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl}-4-hydroxybenzoic acid
13-(6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienal
2-(9-hydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)-6-methylcyclohexa-2,5-diene-1,4-dione
3-{[(1r,4ar,5s,8ar)-5,8a-dimethyl-2-methylidene-5-(4-methylpent-4-en-1-yl)-hexahydro-1h-naphthalen-1-yl]methyl}-4-hydroxybenzoic acid
(1r,3as,3bs,9ar,9bs,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,7-dione
2-{6-[2-(8a-hydroxy-1,2,5,5-tetramethyl-hexahydro-2h-naphthalen-1-yl)ethyl]-6-methyl-1,2-dioxan-3-yl}propanoic acid
2,5,8-trihydroxy-4-(3-hydroxypropanoyl)-4,7-dimethyl-3-(octan-2-yl)-4a,5,6,7,8,8a-hexahydronaphthalen-1-one
(1s,2r,5s,14s,15r,18r,19s)-10-hydroxy-5,15,19-trimethyl-6,21-dioxahexacyclo[17.3.3.0¹,¹⁸.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]pentacosa-7,9,11-trien-20-one
(1r,2r,4r,5z,12r,13r,16z)-13-hydroxy-11,22-diazapentacyclo[11.11.2.1²,²².0²,¹².0⁴,¹¹]heptacosa-5,16,25-triene-25-carbaldehyde
C26H38N2O2 (410.29331279999997)